NCT02254135已完成1 期
A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Peroral Doses (400, 800, 1200 μg Free Cation) BEA 2180 BR in Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Number of subjects with abnormal changes in laboratory parameters
研究概览
简要总结
Study to investigate safety, tolerability, and pharmacokinetics of single rising peroral doses of BEA 2180 BR
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
- •Age ≥21 and ≤55 years
- •BMI ≥18.5 and <30 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR, and ECG measurements) deviating from normal and of clinical relevance
- •Evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients) as judged clinically relevant by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to randomisation
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to enrolment in the study or during the study
- •Participation in another trial with an investigational drug within 30 days prior to randomisation
- •Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- •Inability to refrain from smoking on trial days as judged by the investigator
- •Alcohol abuse (regularly more than 40 g alcohol per day)
- •Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during the trial)
- •Excessive physical activities within 1 week prior to randomisation or during the trial
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of the study centre
- •The following exclusion criteria are specific for this study due to the known class side effect profile of anticholinergic drugs:
- •History of hypersensitivity to tiotropium and/or related drugs of these classes
- •History of narrow-angle glaucoma
- •History of prostatic hyperplasia
- •History of bladder-neck obstruction
研究组 & 干预措施
BEA 2180 BR solution - rising dose
Experimental
干预措施: BEA 2180 BR - rising dose (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of subjects with abnormal changes in laboratory parameters
时间窗: up to 14 days after last procedure
Number of subjects with adverse events
时间窗: up to 14 days after last procedure
Number of subjects with clinically significant changes in 12-lead electrocardiogram (ECG)
时间窗: up to 14 days after last procedure
Number of subjects with abnormal findings in physical examination
时间窗: up to 14 days after last procedure
Number of subjects with clinically significant changes in vital signs
时间窗: up to 14 days after last procedure
(Blood pressure (BP), pulse rate (PR), respiration rate (RR), oral body temperature)
Assessment of tolerability by the investigator on a 4-point scale
时间窗: 14 days after last procedure
次要结局
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 48 h after drug administration)
- %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)(up to 48 h after drug administration)
- Cmax (maximum measured concentration of the analyte in plasma)(up to 48 h after drug administration)
- tmax (time from dosing to maximum measured concentration of the analyte in plasma)(up to 48 h after drug administration)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 48 h after drug administration)
- λz (terminal rate constant in plasma)(up to 48 h after drug administration)
- t1/2 (terminal half-life of the analyte in plasma)(up to 48 h after drug administration)
- MRTpo (mean residence time of the analyte in the body after peroral administration)(up to 48 h after drug administration)
- CL/F (clearance of the analyte in plasma after peroral administration)(up to 48 h after drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following a peroral dose)(up to 48 h after drug administration)
- Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)(up to 48 h after drug administration)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(up to 48 h after drug administration)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(up to 48 h after drug administration)
研究者
相似试验
已完成
1 期
Single Rising Peroral Doses of BI 1744 CL in Healthy VolunteersHealthyNCT02171793Boehringer Ingelheim24
已完成
1 期
To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy SubjectsRheumatoid ArthritisNCT03718611Boryung Pharmaceutical Co., Ltd36
进行中（未招募）
1 期
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult ParticipantsAlpha 1-Antitrypsin DeficiencyNCT06738017BioMarin Pharmaceutical6
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary HyperparathyroidismHyperparathyroidism, SecondaryNCT01134562KAI Pharmaceuticals28
已完成
1 期
A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy SubjectsInfections, Human Immunodeficiency Virus and HerpesviridaeNCT01756131ViiV Healthcare72